[Cefotaxime in childhood infections (author's transl)].
Cefotaxime was administered to 20 patients suffering from severe bacterial infections. Four were newborn babies, seven were infants, and nine were children. The infections treated included 9 bronchopulmonary infections and 6 urinary tract infections. In 9 patients, the infecting organism was identified: E. coli (3), Klebsiella (2), Staphylococcus aureus (3), and Proteus (1). Except in one case, cefotaxime was administered alone at doses of 50 to 100 mg/kg every 12 hours. The route of administration was intramuscular. 4 patients had already received unsuccessful antimicrobial therapy. All patients were clinically cured. In those with pneumonia, the clinical and radiological response was very prompt; in urinary tract infections, the temperature returned to normal in less than 48 hours. The local and general tolerance was always good. It may be concluded from these results that cefotaxime, a new parenteral cephalosporin, is especially useful and should prove particularly effective in severe infectious conditions found in pediatric practice.
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008199:Lymphadenitis / Q000188:drug therapy; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002439:Cefotaxime
Utilisation du céfotaxime dans les maladies infectieuses de l'enfant.